This resolution calls for increased funding and support to improve diagnosis, research, and treatment options for patients battling the rare and aggressive bone cancer, chordoma.
Henry "Hank" Johnson
Representative
GA-4
This resolution raises awareness for chordoma, a rare and aggressive bone cancer affecting the skull and spine that currently lacks effective drug treatments. It calls on the House of Representatives to prioritize increased funding and support for early diagnosis, innovative research, and the development of new, patient-focused cures.
New House Resolution Targets Chordoma: A Push for Research Funding and Faster Diagnostics for Rare Bone Cancer
This resolution officially recognizes chordoma, a rare and aggressive bone cancer that targets the skull and spine, affecting roughly 300 Americans every year. Because these tumors wrap themselves around critical areas like the brain stem and major arteries, they are notoriously difficult to treat, and the bill highlights a sobering reality: there are currently no drugs known to cure or effectively control the disease once surgery and radiation have been exhausted. By formalizing the 'sense of the House,' this measure sets a federal priority to increase funding for early diagnosis and to bridge the gap between lab research and actual bedside treatments.
The Precision Problem
Treating chordoma is like trying to remove a splinter from a spiderweb without breaking a single thread. The bill notes that even with top-tier surgical teams, the recurrence rate is high because the cancer sits on the spinal cord and major nerves. For a patient, this means that even after a 'successful' surgery, the threat of the cancer returning is a constant shadow. By prioritizing 'accurate and early diagnosis,' the resolution aims to catch these slow-growing tumors before they entwine with vital structures, potentially moving the needle from 'management' to 'cure' for the 25,000 people living with this worldwide.
Fast-Tracking the Lab-to-Life Pipeline
One of the biggest hurdles in rare disease advocacy is the 'valley of death'—the gap where promising research dies because there isn't enough funding to turn it into a usable drug. This resolution specifically calls for reducing hurdles between research and new treatments. For a family dealing with a diagnosis today, this could eventually mean access to clinical trials or patient-focused drug developments that didn't exist a year ago. It shifts the focus toward 'patient-focused approaches,' ensuring that the people actually living with the disease have a say in how new diagnostics and cures are developed, rather than just leaving it to the bureaucrats and scientists.